M Parrizas1,2, X Mundet3,4,5, C Castaño1,2, S Canivell4,6,7, X Cos4,6, L Brugnara1,2, C Giráldez-García3,8,9, E Regidor3,9,10,11, M Mata-Cases1,3,4,12, J Franch-Nadal13,14,15,16, A Novials17,18. 1. Spanish Biomedical Research Center in Diabetes and Associated Metabolic Disorders (CIBERDEM), Barcelona, Spain. 2. Pathogenesis and Prevention of Diabetes Laboratory, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Rosselló 149-153, 08036, Barcelona, Spain. 3. redGDPS Foundation, Madrid, Spain. 4. DAP-Cat Group, Research Support Unit, University Institute for Research in Primary Care Jordi Gol (IDIAPJGol), Gran Via de les Corts Catalanes, 587, 08007, Barcelona, Spain. 5. Autonomous University of Barcelona, Barcelona, Spain. 6. Primary Health Care Center Sant Martí de Provençals, Catalan Health Institute, Barcelona, Spain. 7. Department of Internal Medicine, Health Sciences Research Institute and University Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain. 8. Preventive Medicine Service, University Hospital Infanta Elena, Madrid, Spain. 9. Preventive Medicine, Public Health and History of Science Department, Complutense University of Madrid, Madrid, Spain. 10. Epidemiology and Public Health Networking Biomedical Research Centre (CIBERESP), Madrid, Spain. 11. Health Research Institute, Hospital Clínico San Carlos (IdISSC), Madrid, Spain. 12. Primary Health Care Center La Mina, Catalan Health Institute, Sant Adrià De Besòs, Barcelona, Spain. 13. Spanish Biomedical Research Center in Diabetes and Associated Metabolic Disorders (CIBERDEM), Barcelona, Spain. josep.franch@gmail.com. 14. redGDPS Foundation, Madrid, Spain. josep.franch@gmail.com. 15. DAP-Cat Group, Research Support Unit, University Institute for Research in Primary Care Jordi Gol (IDIAPJGol), Gran Via de les Corts Catalanes, 587, 08007, Barcelona, Spain. josep.franch@gmail.com. 16. Department of Medicine, University of Barcelona, Barcelona, Spain. josep.franch@gmail.com. 17. Spanish Biomedical Research Center in Diabetes and Associated Metabolic Disorders (CIBERDEM), Barcelona, Spain. anovials@clinic.cat. 18. Pathogenesis and Prevention of Diabetes Laboratory, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Rosselló 149-153, 08036, Barcelona, Spain. anovials@clinic.cat.
Abstract
PURPOSE: Type 2 diabetes frequently remains undiagnosed for years, whereas early detection of affected individuals would facilitate the implementation of timely and cost-effective therapies, hence decreasing morbidity. With the intention of identifying novel diagnostic biomarkers, we characterized the miRNA profile of microvesicles isolated from retroactive serum samples of normoglycemic individuals and two groups of subjects with prediabetes that in the following 4 years either progressed to overt diabetes or remained stable. METHODS: We profiled miRNAs in serum microvesicles of a selected group of control and prediabetic individuals participating in the PREDAPS cohort study. Half of the subjects with prediabetes were diagnosed with diabetes during the 4 years of follow-up, while the glycemic status of the other half remained unchanged. RESULTS: We identified two miRNAs, miR-10b and miR-223-3p, which target components of the insulin signaling pathway and whose ratio discriminates between these two subgroups of prediabetic individuals at a stage at which other features, including glycemia, are less proficient at separating them. In global, the profile of miRNAs in microvesicles of prediabetic subjects primed to progress to overt diabetes was more similar to that of diabetic patients than the profile of prediabetic subjects who did not progress. CONCLUSION: We have identified a miRNA signature in serum microvesicles that can be used as a new screening biomarker to identify subjects with prediabetes at high risk of developing diabetes, hence allowing the implementation of earlier, and probably more effective, therapeutic interventions.
PURPOSE: Type 2 diabetes frequently remains undiagnosed for years, whereas early detection of affected individuals would facilitate the implementation of timely and cost-effective therapies, hence decreasing morbidity. With the intention of identifying novel diagnostic biomarkers, we characterized the miRNA profile of microvesicles isolated from retroactive serum samples of normoglycemic individuals and two groups of subjects with prediabetes that in the following 4 years either progressed to overt diabetes or remained stable. METHODS: We profiled miRNAs in serum microvesicles of a selected group of control and prediabetic individuals participating in the PREDAPS cohort study. Half of the subjects with prediabetes were diagnosed with diabetes during the 4 years of follow-up, while the glycemic status of the other half remained unchanged. RESULTS: We identified two miRNAs, miR-10b and miR-223-3p, which target components of the insulin signaling pathway and whose ratio discriminates between these two subgroups of prediabetic individuals at a stage at which other features, including glycemia, are less proficient at separating them. In global, the profile of miRNAs in microvesicles of prediabetic subjects primed to progress to overt diabetes was more similar to that of diabetic patients than the profile of prediabetic subjects who did not progress. CONCLUSION: We have identified a miRNA signature in serum microvesicles that can be used as a new screening biomarker to identify subjects with prediabetes at high risk of developing diabetes, hence allowing the implementation of earlier, and probably more effective, therapeutic interventions.
Authors: N H Cho; J E Shaw; S Karuranga; Y Huang; J D da Rocha Fernandes; A W Ohlrogge; B Malanda Journal: Diabetes Res Clin Pract Date: 2018-02-26 Impact factor: 5.602
Authors: Marcelina Párrizas; Laura Brugnara; Yaiza Esteban; Alba González-Franquesa; Sílvia Canivell; Serafín Murillo; Elizabeth Gordillo-Bastidas; Roser Cussó; Joan A Cadefau; Pablo M García-Roves; Joan-Marc Servitja; Anna Novials Journal: J Clin Endocrinol Metab Date: 2014-12-22 Impact factor: 5.958
Authors: F Soriguer; A Goday; A Bosch-Comas; E Bordiú; A Calle-Pascual; R Carmena; R Casamitjana; L Castaño; C Castell; M Catalá; E Delgado; J Franch; S Gaztambide; J Girbés; R Gomis; G Gutiérrez; A López-Alba; M T Martínez-Larrad; E Menéndez; I Mora-Peces; E Ortega; G Pascual-Manich; G Rojo-Martínez; M Serrano-Rios; S Valdés; J A Vázquez; J Vendrell Journal: Diabetologia Date: 2011-10-11 Impact factor: 10.122
Authors: Thomas Thomou; Marcelo A Mori; Jonathan M Dreyfuss; Masahiro Konishi; Masaji Sakaguchi; Christian Wolfrum; Tata Nageswara Rao; Jonathon N Winnay; Ruben Garcia-Martin; Steven K Grinspoon; Phillip Gorden; C Ronald Kahn Journal: Nature Date: 2017-02-15 Impact factor: 49.962
Authors: Lucia La Sala; Maurizio Crestani; Silvia Garavelli; Paola de Candia; Antonio E Pontiroli Journal: Int J Mol Sci Date: 2020-12-25 Impact factor: 5.923